RxDoctor Payments DataLook up a doctor →

David Kocenda

Family · Lapeer, MINPI 1124487665

Payments from drug & device makers

$49,330in general payments, 2019–2025

Across 602 payments — averaging $81.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$36K
  • Si-bone, Inc.$2K
  • Relievant Medsystems, Inc.$2K
  • Medtronic$1K
  • Boston Scientific$1K
  • Novartis$1K
  • plus $7K from 48 others

What the payments were for

  • Speaking & faculty fees$33,39068%
  • Travel & lodging$5,18411%
  • Food & beverage$10,73422%
  • Education$220%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,330 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$30,728
Medicare patients
73
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant25$35,810
Nurtec OdtRimegepant Sulfate17$34,730
NourianzIstradefylline13$24,289
XcopriCenobamate12$13,474
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen360$6,330
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen201$5,001
Pregabalin206$4,849
Gabapentin262$2,833
Ropinirole Hcl100$1,736
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine36$1,393
Tizanidine Hcl151$1,156
Cyclobenzaprine Hcl136$1,151
Morphine Sulfate ErMorphine Sulfate48$1,136
Baclofen107$1,129
Duloxetine Hcl108$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$35,595$35,81025 claims
PfizerNurtec Odt$225$34,73017 claims
Kyowa Kirin, Inc.Nourianz$120$24,28913 claims
SK Life Science, Inc.Xcopri$227$13,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Lapeer

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →